AP448A - Use of hyaluronic acid and forms to prevent arterial restenosis. - Google Patents
Use of hyaluronic acid and forms to prevent arterial restenosis. Download PDFInfo
- Publication number
- AP448A AP448A APAP/P/1993/000568A AP9300568A AP448A AP 448 A AP448 A AP 448A AP 9300568 A AP9300568 A AP 9300568A AP 448 A AP448 A AP 448A
- Authority
- AP
- ARIPO
- Prior art keywords
- hyaluronic acid
- amount
- person
- salts
- administered
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Materials For Medical Uses (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA002079205A CA2079205C (en) | 1992-09-25 | 1992-09-25 | Use of hyaluronic acid and forms to prevent arterial restenosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AP9300568A0 AP9300568A0 (en) | 1993-10-31 |
| AP448A true AP448A (en) | 1996-01-18 |
Family
ID=4150463
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| APAP/P/1993/000568A AP448A (en) | 1992-09-25 | 1993-09-22 | Use of hyaluronic acid and forms to prevent arterial restenosis. |
Country Status (26)
| Country | Link |
|---|---|
| EP (1) | EP0661981B1 (cs) |
| JP (1) | JP3742955B2 (cs) |
| CN (1) | CN1057908C (cs) |
| AP (1) | AP448A (cs) |
| AT (1) | ATE141054T1 (cs) |
| AU (1) | AU670117B2 (cs) |
| BR (1) | BR9307221A (cs) |
| CA (1) | CA2079205C (cs) |
| CZ (1) | CZ288986B6 (cs) |
| DE (1) | DE69303931T2 (cs) |
| DK (1) | DK0661981T3 (cs) |
| ES (1) | ES2091031T3 (cs) |
| GR (1) | GR3021171T3 (cs) |
| HK (1) | HK35397A (cs) |
| HU (2) | HU227067B1 (cs) |
| IL (1) | IL107087A0 (cs) |
| IN (1) | IN181289B (cs) |
| MD (1) | MD960294A (cs) |
| MX (1) | MX9305887A (cs) |
| NO (1) | NO309457B1 (cs) |
| NZ (1) | NZ255978A (cs) |
| PL (1) | PL308201A1 (cs) |
| SG (1) | SG48845A1 (cs) |
| SK (1) | SK36895A3 (cs) |
| TW (1) | TW271401B (cs) |
| ZA (1) | ZA937068B (cs) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5811447A (en) | 1993-01-28 | 1998-09-22 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
| US6515009B1 (en) | 1991-09-27 | 2003-02-04 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
| US5981568A (en) | 1993-01-28 | 1999-11-09 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
| US6491938B2 (en) | 1993-05-13 | 2002-12-10 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
| US6663881B2 (en) | 1993-01-28 | 2003-12-16 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
| EP1005874B1 (en) * | 1997-08-22 | 2005-05-18 | Denki Kagaku Kogyo Kabushiki Kaisha | Hyaluronic acid gel, process for producing the same and medical material containing the same |
| FR2813791B1 (fr) | 2000-09-14 | 2004-03-12 | Lafon Labor | Utilisation de 2- et 4-quinolones pour inhiber la neo-proliferation intimale |
| FR2994846B1 (fr) | 2012-08-29 | 2014-12-26 | Vivacy Lab | Composition, sterilisee, comprenant au moins un acide hyaluronique et de l'ascorbyl phosphate de magnesium |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1340994C (en) * | 1989-09-21 | 2000-05-16 | Rudolf Edgar Dr. Falk | Treatment of conditions and disease |
-
1992
- 1992-09-25 CA CA002079205A patent/CA2079205C/en not_active Expired - Lifetime
-
1993
- 1993-09-22 EP EP93920624A patent/EP0661981B1/en not_active Expired - Lifetime
- 1993-09-22 TW TW082107796A patent/TW271401B/zh active
- 1993-09-22 SK SK368-95A patent/SK36895A3/sk unknown
- 1993-09-22 AU AU48126/93A patent/AU670117B2/en not_active Expired
- 1993-09-22 HU HU9500857A patent/HU227067B1/hu unknown
- 1993-09-22 BR BR9307221A patent/BR9307221A/pt not_active Application Discontinuation
- 1993-09-22 SG SG1996002824A patent/SG48845A1/en unknown
- 1993-09-22 AT AT93920624T patent/ATE141054T1/de active
- 1993-09-22 ES ES93920624T patent/ES2091031T3/es not_active Expired - Lifetime
- 1993-09-22 AP APAP/P/1993/000568A patent/AP448A/en active
- 1993-09-22 MD MD96-0294A patent/MD960294A/ro not_active Application Discontinuation
- 1993-09-22 PL PL93308201A patent/PL308201A1/xx unknown
- 1993-09-22 CZ CZ1995662A patent/CZ288986B6/cs not_active IP Right Cessation
- 1993-09-22 JP JP50854394A patent/JP3742955B2/ja not_active Expired - Lifetime
- 1993-09-22 DE DE69303931T patent/DE69303931T2/de not_active Expired - Lifetime
- 1993-09-22 DK DK93920624.9T patent/DK0661981T3/da active
- 1993-09-22 NZ NZ255978A patent/NZ255978A/en not_active IP Right Cessation
- 1993-09-23 IL IL107087A patent/IL107087A0/xx not_active IP Right Cessation
- 1993-09-24 ZA ZA937068A patent/ZA937068B/xx unknown
- 1993-09-24 MX MX9305887A patent/MX9305887A/es unknown
- 1993-09-24 CN CN93119844A patent/CN1057908C/zh not_active Expired - Fee Related
-
1995
- 1995-03-23 NO NO951122A patent/NO309457B1/no not_active IP Right Cessation
- 1995-06-13 IN IN670CA1995 patent/IN181289B/en unknown
- 1995-06-30 HU HU95P/P00651P patent/HU211698A9/hu unknown
-
1996
- 1996-09-26 GR GR960402522T patent/GR3021171T3/el unknown
-
1997
- 1997-03-20 HK HK35397A patent/HK35397A/xx not_active IP Right Cessation
Non-Patent Citations (1)
| Title |
|---|
| NONE * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6022866A (en) | Use of hyaluronic acid and forms to prevent arterial restenosis | |
| US5614506A (en) | Use of hyaluronic acid and forms to prevent arterial restenosis | |
| US5990095A (en) | Use of hyaluronic acid and forms to prevent arterial restenosis | |
| US5834444A (en) | Hyaluronic acid and salts thereof inhibit arterial restenosis | |
| US20040019011A1 (en) | Treatment of conitions and disease | |
| IL124977A (en) | Oral pharmaceutical compositions containing forms of hyaluronic acid for treating restenosis | |
| AP448A (en) | Use of hyaluronic acid and forms to prevent arterial restenosis. | |
| SK126595A3 (en) | Compositions, for inhibition, control and regression of angiogenesis, containing hyaluronic acid and nsaid | |
| AP619A (en) | Use of hyaluronic acid or salt for the treatment of a human having a stroke or myocardial infarction. | |
| US5817642A (en) | Clearing of atherosclerosis | |
| KR100476782B1 (ko) | 히알루론산수용체결합물질과이의용도 | |
| CA2106695C (en) | Hyaluronic acid and forms to prevent arterial restenosis | |
| JP3811500B2 (ja) | 動脈硬化の除去のためのヒアルロン酸を含む薬剤組成物 | |
| US5817644A (en) | Targeting of dosages of medicine and therapeutic agents | |
| AU702929B2 (en) | Use of hyaluronic acid and forms to prevent arterial restenosis | |
| JP2000513707A (ja) | 投与薬剤の目標化、治療薬および他のグリコサミノグリカン（ｇａｇｓ） | |
| CA2120045C (en) | Use of hyaluronic acid and forms to prevent arterial restenosis | |
| CA2167044C (en) | Oral administration of effective amounts of forms of hyaluronic acid | |
| NZ299942A (en) | Use of hyaluronic acid (or fragments thereof) to prevent narrowing of tubular walls in an animal (typically arterial restenosis) | |
| CA2164260C (en) | Targeting of dosages of medicines and therapeutic agents | |
| CA2131130A1 (en) | Modulation of cellular activity | |
| CA2193921A1 (en) | Oral administration of effective amounts of forms of hyaluronic acid according to various standards |